» Articles » PMID: 25722117

Tonsil-derived Mesenchymal Stem Cells Ameliorate CCl4-induced Liver Fibrosis in Mice Via Autophagy Activation

Overview
Journal Sci Rep
Specialty Science
Date 2015 Feb 28
PMID 25722117
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Liver transplantation is the treatment of choice for chronic liver failure, although it is complicated by donor shortage, surgery-related complications, and immunological rejection. Cell transplantation is an alternative, minimally invasive treatment option with potentially fewer complications. We used human palatine tonsil as a novel source of mesenchymal stem cells (T-MSCs) and examined their ability to differentiate into hepatocyte-like cells in vivo and in vitro. Carbon tetrachloride (CCl4) mouse model was used to investigate the ability of T-MSCs to home to the site of liver injury. T-MSCs were only detected in the damaged liver, suggesting that they are disease-responsive. Differentiation of T-MSCs into hepatocyte-like cells was confirmed in vitro as determined by expression of hepatocyte markers. Next, we showed resolution of liver fibrosis by T-MSCs via reduction of TGF-β expression and collagen deposition in the liver. We hypothesized that autophagy activation was a possible mechanism for T-MSC-mediated liver recovery. In this report, we demonstrate for the first time that T-MSCs can differentiate into hepatocyte-like cells and ameliorate liver fibrosis via autophagy activation and down-regulation of TGF-β. These findings suggest that T-MSCs could be used as a novel source for stem cell therapy targeting liver diseases.

Citing Articles

Mesenchymal Stem Cells and Their Derived Exosomes Mitigated Hepatic Cirrhosis in Rats by Altering the Expression of miR-23b and miR-221.

Abd-Allah S, Khamis T, Samy W, Alsemeh A, Abdullah D, Hussein S Iran J Med Sci. 2024; 49(11):724-740.

PMID: 39678523 PMC: 11645418. DOI: 10.30476/ijms.2023.99524.3159.


Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.

Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y Signal Transduct Target Ther. 2024; 9(1):242.

PMID: 39271680 PMC: 11399464. DOI: 10.1038/s41392-024-01936-8.


Advances and clinical challenges of mesenchymal stem cell therapy.

Mei R, Wan Z, Yang C, Shen X, Wang R, Zhang H Front Immunol. 2024; 15:1421854.

PMID: 39100671 PMC: 11294097. DOI: 10.3389/fimmu.2024.1421854.


Enhanced Intervertebral Disc Repair via Genetically Engineered Mesenchymal Stem Cells with Tetracycline Regulatory System.

Kim Y, An S, Lee S, Lee J, Kim S, Ahn J Int J Mol Sci. 2023; 24(22).

PMID: 38003216 PMC: 10671788. DOI: 10.3390/ijms242216024.


Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy the TGF-β1/Smad pathway: implications for liver cancer.

Peng X, Yang H, Tao L, Xiao J, Zeng Y, Shen Y PeerJ. 2023; 11:e16060.

PMID: 37790613 PMC: 10542821. DOI: 10.7717/peerj.16060.


References
1.
Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X . Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med. 2011; 17(12):1594-601. PMC: 3233650. DOI: 10.1038/nm.2542. View

2.
Joo S, Cho K, Jung Y, Kim H, Park S, Choi Y . Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction. Cell Biol Int. 2010; 35(4):417-21. DOI: 10.1042/CBI20100563. View

3.
Kisseleva T, Brenner D . The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. J Hepatol. 2011; 56(4):965-72. PMC: 3307836. DOI: 10.1016/j.jhep.2011.09.021. View

4.
Russo F, Parola M . Stem cells in liver failure. Best Pract Res Clin Gastroenterol. 2012; 26(1):35-45. DOI: 10.1016/j.bpg.2012.01.001. View

5.
Kim S, Na H, Ding Y, Wang Z, Lee S, Choi M . Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1. J Biol Chem. 2012; 287(15):11677-88. PMC: 3320917. DOI: 10.1074/jbc.M111.308460. View